Japanese drugmaker Astellas Pharma (TYO: 4503) has boosted its senior management team, creating two new positions which will report directly to chief executive Kenji Yasukawa.
While Astellas has been focusing on innovation in transplantation and oncology, in particular prostate cancer, it has taken a strategic decision to invest in the growing area of cell and gene therapies.
This has included the $3 billion purchase of Audentes Therapeutics, a genetic medicines company working on novel treatments for life-threatening conditions, including neuromuscular diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze